Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I/II trial studies the side effects and how well nivolumab and ipilimumab in
combination with chemotherapy and radiation therapy work in treating patients with gastric
cancer that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as
nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Intensity-modulated radiation therapy uses thin beams of radiation of different
strengths aimed at the tumor from many angles. This type of radiation therapy may reduce the
damage to healthy tissue near the tumor. Giving nivolumab, ipilimumab, chemotherapy and
radiation therapy may work better in treating patients with gastric cancer.